Mitochondrial Changes in Alzheimer's Disease
Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias
Recruiting
N/A
Interventional Study
Alzheimer Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 250 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Other
Who this trial is looking for
This trial is looking for people with Alzheimer's disease or related memory issues, as well as healthy volunteers. Participants will provide samples and undergo tests to help researchers understand how these conditions affect cell function.
Are You a Good Fit for This Trial?
You may be able to join if
- I have a neurocognitive disorder for at least 6 months
- I have given my consent to participate
- I am part of a social security scheme
- I have been diagnosed with Alzheimer's disease
- I have been diagnosed with a mild or major neurocognitive disorder
- I have no memory issues if I am a healthy volunteer
- I am an adult
You may not be able to join if
- I am considered a vulnerable person
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This project aims to study on one hand the early mitochondrial alterations, common or specific, occurring in peripheral cells of patients with Alzheimer's disease or related dementia and, on the other hand, identify the metabolomic biomarkers that may be at the origin of mitochondrial disturbances associated with the disease. This will be the first study combining functional analyses of mitochondr…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Neurocognitive disorder with spontaneous complaint or reported for at least 6 months
* Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations.
* cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of …
Contacts